Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure  by Bervoets, An R.J. et al.
see commentary on page 355
Hepatocellular transport and gastrointestinal
absorption of lanthanum in chronic renal failure
An R.J. Bervoets1, Geert J. Behets1, Dominick Schryvers2, Frank Roels3, Zhang Yang2,
Steven C. Verberckmoes1, Stephen J.P. Damment4, Simonne Dauwe1, Valentine K. Mubiana5,
Ronny Blust5, Marc E. De Broe1 and Patrick C. D’Haese1
1Laboratory of Pathophysiology, Faculties of Medicine and Biomedical, Pharmaceutical and Veterinary Sciences, University of Antwerp,
Antwerp, Belgium; 2EMAT, University of Antwerp, Antwerp, Belgium; 3Department of Pathology, Ghent University, Ghent, Belgium;
4Shire Pharmaceutical Development Ltd., Hampshire, UK and 5Department of Biology, University of Antwerp, Antwerp, Belgium
Lanthanum carbonate is a new phosphate binder that is poorly
absorbed from the gastrointestinal tract and eliminated largely
by the liver. After oral treatment, we and others had noticed
2–3 fold higher lanthanum levels in the livers of rats with
chronic renal failure compared to rats with normal renal
function. Here we studied the kinetics and tissue distribution,
absorption, and subcellular localization of lanthanum in the
liver using transmission electron microscopy, electron energy
loss spectrometry, and X-ray fluoresence. We found that in the
liver lanthanum was located in lysosomes and in the biliary
canal but not in any other cellular organelles. This suggests
that lanthanum is transported and eliminated by the liver via a
transcellular, endosomal-lysosomal-biliary canicular transport
route. Feeding rats with chronic renal failure orally with
lanthanum resulted in a doubling of the liver levels compared
to rats with normal renal function, but the serum levels were
similar in both animal groups. These levels plateaued after 6
weeks at a concentration below 3 lg/g in both groups. When
lanthanum was administered intravenously, thereby bypassing
the gastrointestinal tract-portal vein pathway, no difference
in liver levels was found between rats with and without renal
failure. This suggests that there is an increased gastrointestinal
permeability or absorption of oral lanthanum in uremia.
Lanthanum levels in the brain and heart fluctuated near its
detection limit with long-term treatment (20 weeks) having
no effect on organ weight, liver enzyme activities, or liver
histology. We suggest that the kinetics of lanthanum in the
liver are consistent with a transcellular transport pathway, with
higher levels in the liver of uremic rats due to higher intestinal
absorption.
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Control of phosphatemia remains an important challenge in
the management of bone disease, along with the prevention
of vascular calcifications in patients with end-stage renal
failure.1,2 Amongst the currently available phosphate-binding
agents, although relatively efficacious, some of them are
associated with severe adverse and toxic effects.3,4 Recently,
lanthanum (La) carbonate, a trivalent cation and a
noncalcemic phosphate binder, has been introduced as an
efficacious and well-tolerated alternative.5–7 In a study in
which the efficacy of various phosphate binders was
compared in 5/6th nephrectomized rats, La carbonate was
among the most potent ones, as indicated indirectly by its
more pronounced reduction in urinary phosphate excretion.6
Clinical studies have demonstrated that long-term treatment
with La carbonate can maintain control of serum phosphate
levels as a monotherapy with a lower daily tablet burden than
other treatments.8,9
In view of the past experience with aluminum (Al),
information on the absorption, distribution, metabolism,
and excretion of La is essential. The intestinal absorption
of La from the carbonate salt is extremely low
(0.00127±0.00080% in healthy volunteers)10 and approxi-
mately 2–3 orders of magnitude lower than for aluminum,11
resulting in very low serum La concentrations (o1mg/l,
o7.2 nmol/l). Although it is universally accepted that some La
may be found in bone and liver,12,13 there are contradictory
reports about the extent of deposition in other tissues,
especially the brain.14,15 These different profiles could be
explained by a failure to appreciate, and control for, the
substantial risk of tissue contamination in animal studies,
especially those utilizing powdered diets containing La, where
drug concentrations in the animal’s environment may be 7
orders of magnitude higher than in the tissues being
analyzed.16,17 Transfer of small amounts of La from skin and
fur to tissues as animals are manipulated during autopsy can
significantly distort the apparent tissue deposition profile.
The achieved concentrations of La in bone after oral
administration of high doses to rats (2000 mg/kg per day for
up to 12 weeks) or long-term treatment (45 years) in
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humans remain low also when compared to Al and various
other bone-seeking elements. Indeed the highest bone
concentration ever seen in hemodialysis patients after 5 years
of treatment was 70 nmol/g wet weight (10 mg/g). In addition,
using synchrotron-based X-ray fluorescence (XRF), we found
that the ultrastructural localization of La in bone of chronic
renal failure (CRF) rats is of no clinical/toxicological
significance as the element was found at both quiescent
and active sites of bone formation as well as in the deeper
layers of the bone, independent of the type of renal bone
disease.11 In addition, and in contrast to Al no direct toxicity
of La was observed at the level of the osteoblast.
In a clinical bone biopsy-based study in which dialysis
patients were treated with La carbonate for 1 year and
compared to standard therapy, no aluminum-like effect on
bone (osteomalacia, adynamic bone disease) could be
observed,5 which recently was confirmed in a clinical study
over 2 years.18 Moreover, with La carbonate the incidence of
clinically significant hypercalcemia as compared to calcium-
based treatment5 was negligible.
In contrast to Al, which is mainly excreted through the
kidney, elimination of La occurs predominantly through the
liver/bile. Hence, as opposed to Al, renal failure patients are
not expected to be at an increased risk for accumulation of La
as compared to subjects with normal renal function (NRF).19
Data from previous experimental studies in CRF rats orally
loaded with La carbonate however, showed 2- to 3-fold
higher liver La content as compared to rats with NRF
receiving the same dose.12,14 A possible explanation for these
observations could be a more permeable gastrointestinal tract
inherent to the uremic state,20 resulting in a higher La
concentration in the portal vein and increased liver uptake.
This can be investigated indirectly by comparing liver La
levels in CRF versus NRF animals after La loading by either
oral gavage or intravenous administration, as the latter
situation bypasses the gastrointestinal barrier.
In this paper we aimed to find an answer to the following
questions: (1) what is the subcellular localization and liver
handling of La, (2) do liver La levels reach a plateau during
La treatment, (3) is the gastrointestinal absorption of La
increased in CRF?
RESULTS
Study no. 1: subcellular localization of La in the liver
XRF. La localization in the liver of La-loaded rats was
performed using synchrotron-based X-ray microfluorescence
(beamline ID-21; ESRF, Grenoble, France). As with this
technique it is not possible to directly differentiate between
the different compartments of the tissue samples or
subcellular organelles, we performed a comapping of La
with iron known to be mainly stored in liver lysosomes.21
Comparing the mapping profile of La with that of iron the La
signals coincide with sites of high iron signal intensity, thus
indicating La to be localized in the lysosomes of the liver
(Figure 1a1–2).
TEM. To further substantiate the above findings transmis-
sion electron microscopy (TEM) was applied. In the control
animals that had not received La we frequently observed
smooth contoured electron-dense particles within the lyso-
somes (Figure 1b). These were not seen in other subcellular
organelles such as the mitochondria, and most probably are
intracellular or extracellular debris or undigested proteins or
lipids.22 In the La-loaded rats however, aside from these
particles, electron-dense precipitates displaying a crystalline,
granular-like structure, were frequently seen (Figure 1c).
Such particles were not seen in control animals. They were
exclusively found in single-membrane-bound dense bodies
identified as lysosomes, and not in mitochondria, endo-
plasmatic reticulum, peroxisomes, nuclei, or cytoplasm.
Although crystalline deposits were numerous in lysosomes
of liver parenchyma cells, they were either absent or
present at very low levels in those of Ku¨pffer cells. Similar
precipitates were found in bile canaliculi too. The amount of
crystalline material varied strongly between individual
lysosomes; some of them did not contain the electron-dense
precipitate, whereas others were heavily stuffed with dense
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Figure 1 | Subcellular localization of La in the liver. (a) XRF
mapping of La (1) and Fe (2) in liver samples of La-loaded rats
showing co-localization of both elements. (b) TEM image of liver
tissue of rat with normal renal function not exposed to La
showing smoothly contoured electron-dense particles within the
lysosomes. (c) TEM image of liver tissue of La-loaded rat (dose:
0.3 mg/kg per day i.v., 4 weeks) showing electron-dense
precipitates displaying a crystalline granular structure within the
lysosomes. (d) EELS spectrum of electron-dense particles within
lysosomes of liver tissue of La-loaded rat (dose: 0.3 mg/kg per day
i.v., 4 weeks) evidencing the presence of La. (e) TEM image of liver
tissue of La-loaded rats (dose: 0.3 mg/kg per day i.v., 4 weeks) with
La being present in the bile canaliculus (artificially colored in
brown for educational purposes). White arrows show
mitochondria whereas black arrows indicate lysosomes.
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crystals. Although at first observation, the lysosomal
compartment of La-treated animals did not seem to be
enlarged, the mean diameter (mean: 0.662mm, range
o0.32 mm (N¼ 34)) of lysosomes containing the granular
structure was slightly higher than that of the precipitate
negative lysosomes pooled from treated as well as control
animals (mean 0.469 mm, range 0.2–0.82 mm; P¼ 0.0372).
Values noted in both groups were exactly within the normal
range (0.2–0.8 mm).22
EELS. To finally identify these granular structures,
electron energy loss spectroscopy (EELS) was applied. Using
this technique it could clearly be shown that the precipitates
contained La as indicated by the specific M5 and M4 edges,
produced by 3d electrons of the M shell and having onsets at
832 and 849 eV, respectively (Figure 1d). No signal was
observed when examining the lysosomal smoothly contoured
deposits or the various organelles of the control animals.
EELS data further confirmed the TEM results as in the
La-loaded animals no signals were found when examining
mitochondria, endoplasmatic reticulum, peroxisomes, nuclei,
or cytoplasma. Furthermore, using EELS we were able to
demonstrate La-containing precipitates to be exclusively
present in lysosomes, often in close proximity of as well as
within the bile canaliculi (Figure 1e).
In vitro uptake of transferrin-bound La (La-Tf) by primary
cultures of rat hepatocytes. To check whether the unique
presence of La in the lysosomes resulted from Tf-receptor-
mediated uptake of the element an in vitro experiment was
set up in which primary cultures of rat hepatocytes were
incubated with serum-free culture medium containing the
La-Tf complex at varying physiologically relevant concentra-
tions of La (0–25 mg/l). Rat hepatocyte cultures showed a
concentration- and time-dependent La uptake (Figure 2).
The intracellular uptake was accompanied by a concentra-
tion- and time-dependent decrease of the La concentration in
the cell culture medium. When La was added to the serum-
free culture medium as LaCl3 in the absence of Tf however,
no intracellular La could be detected.
Study no. 2: La kinetics in liver and other tissues
During the whole study period, body weight of CRF rats was
lower than that of NRF (364±60 versus 410±71 g at killing).
There were no differences in food consumption between
groups (mean food intake per day: 20±8 versus 20±7
g/day), whereas water intake was increased in CRF (mean
water intake per day 60±16 versus 38±11 ml/day).
Biochemical data presented in Table 1 indicate that 5/6th
nephrectomy induced a moderate CRF as indicated by the
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Figure 2 | La concentration in rat hepatocytes after incubation
with serum-free cell culture medium containing 0, 2.5, 5.0,
and 25.0 lg/l La as the La-Tf complex. Results show a time- and
dose-dependent intracellular uptake of La by the hepatocytes.
Data represent the mean±s.d. La concentration of 4 wells per
condition and per time point.
Table 1 | Blood and urinary biochemical parameters, before and during La loading and at killing (study no. 2)
Baseline Day 1 Week 1 Week 3 Week 6 Week 12 Week 20
Serum calcium (mg/100 ml)
CRF 9.1±0.8 9.7±1.3 9.3±1.5 10.6±1.4 10.2±1.3 11.4±0.3
NRF 10.6±1.5 9.8±1.1 9±1.2 10.8±1.5 10.1±0.7 10.6±1.0 10.6±1.6
Serum phosphate (mg/100 ml)
CRF 5.5±1.4 7.6±1.5 8.2±0.6 8.1±1.5 6.0±2.8 9.2±1.8
NRF 8.2±2.4 7.2±1.2 6.8±1.4 8.6±1.8 7.3±0.8 6.9±0.7 6.6±1.3
Serum creatinine (mg/100 ml)
CRF 0.9±0.4 1.0±0.2 1.3±0.7 1.7±0.6 1.8±1.1 1.7±0.4
NRF 0.4±0.1 0.4±0.1 0.3±0.1 0.5±0.1 0.5±0.1 0.5±0.1 0.6±0.1
Urinary protein (mg/day)
CRF 21.1±8.8 87.6±87.1 ND ND 199.5±142.8 107.6±126.0
NRF 10.8±2.5 11.0±2.6 7.6±2.1 ND ND 14.4±2.8 9.0±4.6
Urinary creatinine (mg/day)
CRF 12.2±2.0 13.2±3.7 ND ND 12.3±6.6 8.3±8.8
NRF 5.6±2.3 14.5±2.0 16.3±1.5 ND ND 21.2±14.3 14.7±5.7
Urinary phosphate (mg/day)
CRF 8.8±2.8 5.3±4.4 ND ND 5.6±5.1 1.2±1.3
NRF 24.2±4.6 19.6±12.6 17.7±15.1 ND ND 10.2±3.9 3.4±3.5
CRF, chronic renal failure; ND, not determined; NRF, normal renal function.
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increased serum creatinine levels in CRF versus NRF rats.
During the whole study period no differences in serum P and
Ca levels were seen between groups at any time point.
Urinary protein increased in CRF. Urinary phosphate
decreased under La treatment (Table 1).
In both groups long-term La treatment had no effect on
liver enzymes (ASAT, ALAT) or liver alkaline phosphatase
(ALP; Figure 3a–c). La loading did not have any effect on
liver weight (Figure 3d) nor on any of the other tissues under
study.
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Figure 3 | Liver enzymes and liver weight in study no. 2. Liver enzymes at killing: (a) ALAT, (b) ASAT, (c) liver ALP, and (d) liver weight
versus body weight (%). *Po0.05 versus normal renal function and #Po0.05 versus previous time point.
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Figure 4 | Organ La content in study no. 2. Organ La content: (a) brain, (b) heart, (c) spleen, (d) bone. *Po0.05 versus normal renal
function; #Po0.05 versus previous time points.
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Light microscopy could not reveal any differences or
effects of La treatment on liver morphology, the presence of
fibrosis or iron content (used as a lysosomal marker).
Baseline serum La levels (before start of treatment) were
0.049±0.042 and 0.73±0.33 mg/l in CRF and 1.07±0.97 mg/l
in NRF at killing (after 20 weeks of treatment), respectively.
In both CRF and NRF rats brain La levels fluctuated
around the lower limit of quantification (LLoQ) at all time
points and there was no increase with time on La treatment
(Figure 4a). Also there was no difference in the heart and
spleen La levels between both groups. Whereas heart La
concentrations leveled off at a concentration below 0.04 mg/g
(Figure 4b), spleen La concentrations steadily increased
during treatment, however did not exceed 0.2 mg/g (Figure
4c). In contrast to these tissues, during the whole study
period, bone La levels were higher in CRF animals as
compared to NRF animals (Figure 4d).
With regard to the liver La concentration, the differences
between NRF and CRF were more pronounced reaching
twice the value in CRF as compared to NRF. With regard to
the element’s kinetics in this organ however, a concentration
plateau was seen in both groups after 6 weeks of treatment
(Figure 5).
Study no. 3: effect of uremia on gastrointestinal absorption
of La
After 4 weeks of intravenous La loading no difference was
noticed between the liver La levels of the CRF groups versus
the NRF animals (Figure 6). However, in rats that were
loaded orally with La, liver La levels in the CRF groups were
twofold higher as compared to those of the NRF group
(1.5±0.5 versus 0.75±0.7 mg/g, Po0.05).
DISCUSSION
La carbonate is a phosphate binder not accumulated in the
serum of dialysis patients as its excretion is by the liver and
not by the kidneys. As the liver is the main excretory organ of
La, it is not surprising that in experimental studies a tissue/
serum La concentration gradient is observed in this particular
organ.12,14 Moreover, in previous experimental studies from
our group and others,14,23 liver La levels in CRF were 2- to 3-
fold higher as compared to those observed in animals with
NRF, suggesting an increased gastrointestinal absorption/
permeability of the element in CRF. Hence insight into the
liver handling and unravelling the mechanisms whereby
higher La concentrations are found in the liver of CRF rats
are mandatory.
The first step in evaluating the safety of a particular metal
or a drug, in this case La, is its detection and subcellular
localization in the target organ. The use of sensitive
techniques such as synchrotron-based XRF, TEM, and EELS
revealed that La was found in lysosomes.24 In this study La
was observed in lysosomes particularly in close proximity to
and also within the bile canaliculi and not in or attached to
any other subcellular organelle. These findings led us to
propose a mechanism of liver handling of La (Figure 7). As
La strongly binds proteins25 such as Tf, the element enters the
hepatocyte by Tf-receptor-mediated endocytosis. The endo-
somes then fuse with the hepatocellular lysosomes. The low
pH present in the endolysosomal compartment results in
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Figure 5 | Liver La concentration during 20 weeks of oral La
loading, data indicate liver La levels reached a plateau after 6
weeks of La loading in both NRF and CRF animals. *Po0.05
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Figure 7 | Proposed transhepatocellular transport mechanism
of La.
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release of La from its carrier protein (that is Tf that is
recycled) and subsequent binding of the element to the
phosphate-rich substances in the lysosomes, including
phosphoproteins and phospholipids. After fusion of the
lysosomal membrane with the membrane of the biliary
canaliculus, lysosomes release their content into bile
(exocytosis).26 Hence, the finding of La in the hepatocytic
lysosomes/biliary canaliculi reflects the element’s major
excretion route.10 Data of our in vitro experiment provide
further evidence for La to be taken up by Tf-receptor-
mediated endosomal/lysosomal pathway and are indicative
for fluid-phase uptake to be marginal or even negligible.
Using Perl’s staining as a surrogate marker for lysosomes,
we did not observe any effect of La on the number of
lysosomes. Also there was no effect of La on the morphology
of lysosomes or any other subcellular organelle such as the
mitochondria, nucleus, and so on; this notwithstanding the
exaggerated concentrations that were achieved in the liver of
these animals (30–50 mg/g) due to the high intravenous La
doses administered. In the presence of these high concentra-
tions we noticed a slightly enlarged lysosomal diameter. This
is not surprising as trapping and subsequent deposition into
the lysosomes will slightly increase the local amorality and
hence the lysosomal volume. No changes in shape were
observed with La and the change in diameter was only mild
remaining within the normal range, this in contrast to rat
lysosomes in iron overload,27 copper overload26 or compared
to lysosomal aminoglycoside accumulation in patients.28
In a following series of experiments we studied the
pharmacokinetics of La in the liver and some other tissues.
We found after 6 weeks of La-treatment plateauing of the
liver La levels in both CRF and NRF animals which lasted till
killing, that is for up to 20 weeks of La treatment indicating
an equilibrium between La uptake at the sinusoidal
membrane and its elimination at the biliary pool. In this
context data of Damment et al. are worth mentioning as they
have demonstrated a similar threshold in normal rats treated
during a 78-week study,29 and an 80% decrease in liver La
levels within 4 weeks after arrest of La administration
(personal communication).
Whereas in NRF rats liver La concentrations leveled off
around 1 mg/g plateauing, in CRF it occurred at 2 mg/g wet
weight. No difference in serum La levels was observed
between CRF and NRF animals. The time point at which half
the maximal La concentration was achieved (Km) was
comparable (2.5 weeks) in CRF versus NRF animals,
indicating that the uremic state per se had no effect on the
uptake rate of La in the liver. The higher steady-state levels in
CRF animals are most likely due to a slight increase in
gastrointestinal absorption in uremia, hence higher La
concentration in the portal vein. A higher gastrointestinal
absorption of La in CRF as compared to NRF animals has
also been suggested by Lacour et al.14 be it without any
experimental support.
In a next step liver La levels in CRF versus NRF animals
that were treated with La for 4 weeks by either oral loading or
intravenous dosing were compared. This allowed us to
differentiate between La entering the liver through the
hepatic portal system (dietary loading—gastrointestinal
absorption) and its direct entrance from the systemic
circulation (intravenous loading), thus bypassing the effect
of gastrointestinal absorption (vena porta). The fact that a
significant difference was found in the liver La concentration
of orally loaded NRF versus CRF animals, in contrast to the
intravenously loaded rats, presents strong indirect evidence
for a slightly higher gastrointestinal absorption/permeability
of La in the uremic state. Magnusson et al.,30 in models of
acute and CRF showed that the intestinal barrier function,
measured by differently sized PEGs, was impaired in CRF.
Uremia, particularly the hemodialyzed patient, has to be
considered as an inflammatory state31 whereby Th1 cells and
several inflammatory markers, such as C-reactive protein,
tumor-necrosis factor-a, interferon-g are found increased in
the serum.32,33 In vitro studies using intestinal cell culture
systems have demonstrated that interferon-g alters epithelial
cell functions such as transepithelial resistance and the
loosening of tight junctions, effects modulated by tumor-
necrosis factor-a.34 Interferon-g in combination with tumor-
necrosis factor-a results in a decrease of claudins 2 and 3,
redistribution of claudin 4 (claudin proteins are a recently
described family of tight junction proteins) followed by an
increase in paracellular permeability. How far this in vitro
observation can be extrapolated to the uremic gastrointest-
inal tract remains to be determined. In this context it is worth
mentioning that uremia has also been reported to enhance
the gastrointestinal absorption of Al.35 Whether the finding
of an increased intestinal absorption of La in CRF
extrapolates from rats to humans is unclear. If it does occur,
it is likely to be limited, as the systemic plasma La
concentration has been shown to be comparable in healthy
human subjects and dialysis patients.36
Liver La leveIs reported in this study are comparable to
those reported by others in which either rats with 5/6th
nephrectomy or adenine-induced CRF were loaded with La
for either 4 or 15 weeks at comparable doses.12,14 The highest
hepatic concentration of La ever reported after oral
administration in a uremic rat model is approximately
3 mg/g wet weight.12 Considering the fact that the normal
concentrations of other lysosomally transported metals such
as copper and iron are in the range of 50 and 2000 mg/g wet
weight, respectively,29 it would appear unlikely that La
treatment would lead to lysosomal overload toxicity. During
20 weeks of La treatment liver biochemistry did not show any
sign of hepatotoxicity, neither on hepatocytes nor on the
hepatobiliary system. In CRF rats loaded with La (1.5%
elemental La in the diet) up to 15 weeks not any histological
abnormality could be detected by either light or electron
microscopy. Similarly, after 3 years of treatment of dialysis
patients with La carbonate at daily doses varying between 1
and 4 g/day no biochemical disturbances or clinical hepato-
toxicity have been observed.8 In contrast to Lacour et al.,14 we
did not observe any effect of La treatment on liver weight or
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on liver/total body weight ratio. It should be mentioned
however, that Lacour et al. normalized liver weight for femur
length which is unconventional as drugs affecting body mass
do not influence this parameter. Indeed when liver weights
were normalized for body mass Rambeck37 demonstrated
that group differences were abolished.
Aside from liver, we also assessed La kinetics in various
other tissues. La kinetics in bone showed slightly higher levels
(although still below 2 mg/g after 20 weeks of high-dose
treatment) in CRF as compared to NRF, which may in part be
due to the increased bone turnover inherent to CRF resulting
in a higher incorporation rate of La in bone. As in CRF rats
bone turnover increases with time of CRF38 no plateauing of
bone La levels is seen in these animals in contrast to NRF.
Similar results were reported by Slatopolsky et al.12
Compared to the liver, La levels in spleen are 1 order of
magnitude lower and do not differ between CRF and NRF
neither did they reach a plateau.
Heart and brain La levels were also comparable between
CRF and NRF groups and after 20 weeks of La treatment
remained as low as 0.03 and o0.01 mg/g, respectively, and
thus fluctuated around the LLoQ. These very low brain levels
(pmol range) are not surprising in view of the high protein
binding of La. They are in line with data from previous
studies performed in animals exposed to large doses of La
carbonate in which it has been shown that La cannot pass the
tight junctions of the blood–brain barrier.39 They further
support the contention that contamination significantly
influenced brain and some other tissue concentrations
reported by some investigators.14,15 Importantly, a recent
2-year, multicenter, comparative study of La carbonate40
demonstrated that La treatment has no adverse effects on
cognitive function in dialysis patients as compared with
standard therapy.
CONCLUSION
The present investigations have demonstrated that the
transcellular (endosomal–lysosomal–biliary canicular) trans-
port/elimination of lanthanum results in plateauing of the
liver La concentration after approximately 6 weeks of oral
treatment. Twofold higher liver La concentrations in the CRF
animals were indirectly shown to be due to a slightly higher
intestinal absorption in the uremic state in this CRF model.
However, plateau concentrations were always less than 3mg/g
and no adverse effects on the liver occurred despite the
prolonged treatment (20 weeks) period adopted in the
studies.
MATERIALS AND METHODS
Study setup
Study no. 1: subcellular localization of La in the liver. Several
techniques (TEM, EELS, synchrotron-based XRF) were applied to
assess the subcellular localization of La in the liver of four NRF rats
that received a daily intravenous La dose (administered as
LaCl3  7H2O) of 0.3 mg/kg for 4 weeks. Rats that had not received
La were used as controls.
In vitro uptake of transferrin-bound La by primary cultures of
rat hepatocytes. Preparation of La-Tf: A La-Tf stock solution was
prepared by overnight incubation at 37 1C of apo-Tf with an
equivalent amount of La taking into account that each Tf molecule
has two binding sites for La. This solution was then further diluted
300-, 1500-, and 3000-fold in serum-free culture medium yielding
physiologically relevant La concentrations of 25.0, 5.0, and 2.5 mg/l,
respectively.
Primary culture of rat hepatocytes: Rat hepatocytes were isolated
from male Sprague–Dawley rat livers as previously described.41
Hepatocytes (viability 480%) were cultured as a monolayer in
serum-free medium at the appropriate density in cell culture
plates.42 After 24 h incubation in serum-free medium, we added
La-Tf to the culture medium yielding a final concentration of
elemental La of 0, 2.5, 5.0, and 25.0 mg/l respectively. Cells were
incubated with La-Tf during 2, 4, 8, and 24 h, respectively, and cells
were lysated after thorough rinsing (3 ) in Tris buffer. La was then
determined in the cellular lysate and culture medium using
inductively coupled plasma-mass spectometry (ICP-MS).
Study no. 2: La kinetics in liver and other tissues. The La
concentration in the liver and other tissues (bone, brain, spleen,
heart) was quantified as a function of time. Wistar rats (87 males)
were either sham operated or 5/6th nephrectomized and loaded
orally (6 days/week) with La carbonate (1000 mg/kg) for 0
(baseline), 1 day, or 1, 3, 6, 12, or 20 weeks (Figure 8).
Study no. 3: effect of uremia on gastrointestinal absorption of
La. In this study 36 animals were either sham operated or 5/6th
nephrectomized and received La for 4 weeks either by oral gavage or
by intravenous injection bypassing the portal vein. Animals were
gavaged 6 days a week (1000 mg/kg) in the morning, whereas
intravenous injection took place 3 times a week in the morning
(Figure 9).
Animals and diets
Male Wistar rats (IFFA Credo, L’Arbresle, Belgium) were housed two
per cage in type III polycarbonate cages throughout the study
period. The rats were exposed to a light cycle of 12 h on/12 h off.
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Figure 8 | Study setup of study no. 2. Animals received 1000 mg/
kg per day La carbonate 6 days a week by oral gavage. At each
time point at least six animals per group of CRF or NRF were killed.
Biochemical blood analysis was performed before induction of
CRF, at the start of the oral loading and at killing.
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Temperature (24 1C) and humidity (60–70%) were kept constant.
The general condition of the animals was monitored daily.
Moribund animals were killed before the end of the study period.
Food consumption was recorded when animals were housed in
metabolic cages (type 3700M0-000; Techniplast, Dison, Belgium).
Animals were fed a pelleted rodent diet with a 0.7% phosphate and
0.8% calcium content prepared by SNIFF Spezialdia¨ten (Soest,
Germany) and had free access to food and water throughout the
study period. In metabolic cages, the animals continued their
assigned diets in powdered form. Body weight was monitored twice
a week or more frequently if the condition of the animals warranted
closer follow-up. All animal procedures were carried out in
accordance with the NIH guide for the care and use of laboratory
animals No. 85-23 (1985) and after approval of the Antwerp
University Ethics Committee for animal studies.
Installation of chronic renal failure
In studies no. 2 and no. 3 CRF was induced by 5/6th nephrectomy
(‘remnant kidney’ rat model). Two branches of the renal artery of
the left kidney were ligated followed by a right nephrectomy 1 week
later. By doing so the remaining renal mass corresponded with
approximately 1/6th of the total original renal mass. Sham-operated
animals served as controls with NRF. Dosing started after a 2-week
stabilization period.
La dosing
For oral dosing in studies no. 2 and no. 3, rats received a daily dose
of 1000 mg/kg of La carbonate suspended in 0.5% carboxymethyl-
cellulose by oral gavage using the procedure applied in previous
experiments.13,43 La was administered in the morning and the dose
adjusted to the most recently recorded body weight. La carbonate
was obtained from Shire Pharmaceutical Development Ltd.
(Basingstoke, UK) as La2(CO3)3  4H2O.
For intravenous dosing (study no. 3), La was administered as La
chloride (LaCl3  7H2O) (Fluka, Deisenhofen, Germany) at a
0.10 mg/kg per 2 days dose. The La chloride solution was prepared
freshly each day by dissolving the appropriate amount of
LaCl3  7H2O in 0.9% of saline. This solution (0.1 mg/ml) was
filter-sterilized before injection, and each animal received a 100 ml/
100 g dose through the tail vein, calculated according to the most
recently recorded body weight. The total amount of LaCl3  7H2O
thus administered during the loading period was: 1.4 mg/kg
LaCl3  7H2O/kg rat weight corresponding with a total elemental
La dose of: 0.52 mg La/kg rat weight.
The same procedure was used for intravenous dosing in study
no. 1, except that a 0.3 mg/kg per day dose was used instead.
Follow-up (studies no. 2 and no. 3)
Before induction of CRF, before the start of the La loading, and
before killing, animals were transferred to metabolic cages for 24 h
urine collection, followed by blood sampling. Urine volume, food,
and water consumption were recorded at the end of the collection
period. After dipstick analysis, urine samples were frozen at 20 1C
until further analysis.
Blood was drawn from the tail vein in restrained animals and
blood samples were immediately placed on ice. After clotting, blood
samples were centrifuged at high speed. The harvested serum was
divided in two fractions and stored at 80 and 20 1C, respectively,
until further analysis.
Killing and tissue sampling
In study no. 2, killing occurred 1 day after the end of La dosing,
whereas in study no. 3, animals were exsanguinated 1 week after the
last La treatment. After anesthesia with sodium pentobarbital
(Nembutal) 60 mg/kg, the animals were exsanguinated through the
aorta abdominalis. Organs were removed and immediately wet
weighed in such an order that the risk for cross-contamination with
La from other organs would be minimal; that is brains, liver, kidney,
spleen, lung, heart, bone. As stomach and intestines may contain
high amounts of La relative to the other organs, these were removed
on another table to further prevent crossover contamination. In
between the animals’ dissection all materials and equipment were
thoroughly washed and dried and new containers were used. Organs
were weighed intact and then cut up in different pieces. One part of
each sampled tissue and the left femur were wet weighed and stored
dry for bulk La analysis by ICP-AES or ICP-MS. Liver samples of
La-treated as well as untreated animals of study no. 1 were cut in
fragments and fixed in 4% formaldehyde in phosphate buffer and
postfixed in reduced OsO4. After dehydration and embedding in
Epon, 100- and 500-nm sections were made and used with or
without counterstaining with uranyl acetate and lead citrate.
Although the 500-nm sections show considerable detail at low
magnifications in a TEM and ensure the observation of many
features in a single section, the results presented in this article were
all obtained using 100-nm sections, stained or unstained.
Biochemical analysis
Serum creatinine, urea, P, and Ca were measured on a routine
autoanalyzer system (Vitros 750 XRC) at the Antwerp University
Hospital as were liver enzymes ASAT and ALAT. Total total ALP
activity was determined spectrophotometrically by kinetic measure-
ment of the release of p-nitro phenol from p-nitro phenol-
phosphate.44 The liver isoenzyme of ALP (liver ALP) was
determined using a modified method by Van Hoof et al.45
Dipstick analysis was performed for pH, leukocytes, glucosuria,
hematuria, and (uro)bilinogen. Urinary creatinine content was
measured with a colorimetric method (Creatinine Merckotest;
Diagnostica Merck, Darmstadt, Germany). Urinary protein content
was measured with the Bradford method.46 Urinary phosphate
content was determined colorimetrically with the Ecoline Sþ
phosphate kit (DiaSys Diagnostic Systems, Holzheim, Germany)
according to the manufacturer’s instructions.
For La analysis, tissue samples were weighed on a precision
balance and subsequently digested overnight in 65% nitric acid at
65 1C. Subsequently, the tissue digests were adjusted to a final
volume of 2 ml with MilliQ water. The La concentration in these
samples was measured with either ICP-AES (Liberty Series II; Varian
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Australia) or ICP-MS (Varian, Melbourne, Australia) depending on
the La concentration. The LLoQ for the determination of La in
serum was 0.004 mg/l whereas for tissues the LLoQ was 0.004 mg/g
for a sample weighing 100 mg. The Ca concentration in the various
organs was measured by flame atomic absorption spectrometry
(Mod. 372; Perkin-Elmer, USA). Bulk tissue content of La and Ca
are expressed in mg/g and mg/g wet weight tissue, respectively.
Histology
Liver tissue was stained with hematoxylin–eosin for histomorpho-
logical examination, Trichrome-Masson for the presence of fibrosis
and Perl’s stain as a surrogate lysosomal marker.
Subcellular localization of La in the liver (study no. 1)
For the subcellular localization of La in the liver, liver fragments of
NRF rats were fixed in 4% formaldehyde in phosphate buffer. Liver
samples of rats that had received vehicle were used as negative
controls.
Synchrotron-based X-ray fluorescence. Subcellular localiza-
tion of La in liver samples was investigated at first instance by means
of synchrotron-based XRF. Given the possibility for a heterogeneous
distribution of La, in combination with the element’s low
concentration (p.p.m. range) an XRF technique with a high spatial
resolution and high sensitivity is required. Synchrotron facilities of
the third generation such as the European Synchrotron Radiation
Facility (ESRF) in Grenoble, France, offer the possibility to generate
hard polychromatic X-rays with a brilliancy being a thousand billion
times higher than those produced by conventional X-ray tubes. This
together with the application of highly advanced focussing
optics provides intense X-ray microprobes for spatially resolved
microanalysis. Synchrotron-based XRF analysis was performed on
10 mm thick paraffin-embedded unstained sections.
Transmission electron microscopy. For TEM analysis samples
were postfixed in reduced OsO4. After dehydration and embedding
in Epon, 100 and 500 nm sections were examined with a Zeiss TEM
(at 50 kV) or Philips TE (at 80 kV) either without, or after
counterstaining with lead citrate, at magnifications varying between
 1800 and  85,000. Owing to its relative high electron density
and granular aspect La is well visualized and has been used as an
ultrastructural tracer.47
Electron energy loss spectroscopy. For the subcellular locali-
zation of La we used focused probe EELS in a transmission electron
microscope (TEM). By using this technique, an energy spectrum is
generated by passing the electrons (that have been scattered
inelastically in the material) through a magnetic prism. It results
in an element-specific energy loss spectrum, which for La is
produced by the 3d electrons of the M shell that are excited into the
empty energy states above the Fermi level. These particular
excitations yield onsets of so-called edges at 832 eV (M5) and
849 eV (M4), which can be detected in a spectral energy range of
about 3 keV, depending on the actual settings of the instrument. The
TEM and EELS work was performed on a CM30 FEI instrument
operating at 300 keV and equipped with a field emission gun and a
post-column Gatan Imaging Filter (GIF2000). Owing to the high
energy and intensity of the impinging electrons, the cross-sectioned
samples of embedded material need to be coated with an
amorphous and conducting carbon film in order for the sections
to remain stable in the microscope. The sections were microtomed
to a thickness of 500 nm, which is rather thick for regular EELS
work. Still, the relatively low contrast typical for these high-tension
machines equipped with a field emission gun gun, which is further
enhanced by the low density of the regular tissue, implied that lead
stained samples had to be used to ensure easy localization of the
tissue. As in these samples, the lysosomal structure is clearly visible,
one can focus the electron beam onto the particular structures in the
lysosome or other cell organelles. In practice, slightly depending on
the actual sample and location, a probe with a diameter in the
micron range was used which was sufficient to investigate selected
regions within the lysosomes having a mean diameter around
0.50mm.
Statistical analysis
Results are shown as mean±s.d. (unless stated otherwise). Statistical
analysis was performed with SPSS 12.0 statistical software. For each
time point and variable, a Kruskal–Wallis test was performed to test
for differences between groups, followed by a Mann–Whitney U-test
with Bonferroni correction when significant differences between
groups were found. Differences between groups were considered
significant when Po0.05.
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